secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2022-10-11T23:59:59+00:00
Accession:  0001104659-22-107725
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel drops wAIHA sNDA after FDA feedback; cuts 16% workforce, 30 jobs
----------------------------------------------------------------------

- FDA guidance on FORWARD Phase 3 re-analysis leads Rigel to halt sNDA for fostamatinib in wAIHA.
- Workforce reduction of 16% (30 positions) primarily in development and admin; completion by Jan 31, 2023.
- One-time cash severance charge of ~$1.5M in Q4 2022; expects $7-8M annual savings from 2023.
- General counsel Dolly Vance retires effective Oct 11, 2022; remains as employee through Nov 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922107725/0001104659-22-107725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922107725/tm2227881d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-107725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer